Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Knee Arthroplasty, Total
Interventions
DRUG

Liposomal Bupivacaine

10 ml of 0.25% bupivacaine expanded with 133 mg (10 ml volume) of liposomal bupivacaine into both the adductor canal and iPACK blocks (total of 40 ml)

DRUG

Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination

20 ml of solution consisting of 0.25% bupivacaine, 1.667mcg/ml of clonidine, 1:400,000 epinephrine, 0.15 mg total of buprenorphine, and 2 mg total of preservative free dexamethasone which will be used in both the adductor canal block and iPACK block (total of 40 ml)

Trial Locations (1)

27157

Atrium Health Wake Forest Baptist, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER